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Abstract
Background: A major clinical issue affecting 10-40% of cancer patients treated with oxaliplatin is severe peripheral
neuropathy with symptoms including cold sensitivity and neuropathic pain. Rat models have been used to
describe the pathological features of oxaliplatin-induced peripheral neuropathy; however, they are inadequate for
parallel studies of oxaliplatin’s antineoplastic activity and neurotoxicity because most cancer models are developed
in mice. Thus, we characterized the effects of chronic, bi-weekly administration of oxaliplatin in BALB/c mice. We
first studied oxaliplatin’s effects on the peripheral nervous system by measuring caudal and digital nerve
conduction velocities (NCV) followed by ultrastructural and morphometric analyses of dorsal root ganglia (DRG)
and sciatic nerves. To further characterize the model, we examined nocifensive behavior and central nervous
system excitability by in vivo electrophysiological recording of spinal dorsal horn (SDH) wide dynamic range
neurons in oxaliplatin-treated mice
Results: We found significantly decreased NCV and action potential amplitude after oxaliplatin treatment along
with neuronal atrophy and multinucleolated DRG neurons that have eccentric nucleoli. Oxaliplatin also induced
significant mechanical allodynia and cold hyperalgesia, starting from the first week of treatment, and a significant
increase in the activity of wide dynamic range neurons in the SDH.
Conclusions: Our findings demonstrate that chronic treatment with oxaliplatin produces neurotoxic changes in
BALB/c mice, confirming that this model is a suitable tool to conduct further mechanistic studies of oxaliplatin-
related antineoplastic activity, peripheral neurotoxicity and pain. Further, this model can be used for the preclinical
discovery of new neuroprotective and analgesic compounds.
Keywords: Oxaliplatin peripheral neuropathy, cold hyperalgesia, mechanical allodynia, dorsal root ganglia, spinal
dorsal horn, electrophysiology
Background
Oxaliplatin is an effective platinum-based drug used as
first line chemotherapy for metastatic colorectal cancer
[1]. Moreover it has been used to treat some cisplatin-
resistant cancers, including those of the stomach [2],
pancreas [3], ovary [4], breast and lung [5]. Oxaliplatin
induces DNA crosslinks that cause apoptotic death of
dividing cells [6] and reduced tumor growth. Unfortu-
nately, the platinum derivative drugs have a molecular
affinity for the peripheral nervous system [7,8], leading
to severe peripheral neurotoxicity that affects most can-
cer patients treated with oxaliplatin-based chemother-
apy. Oxaliplatin-induced peripheral neuropathy is
clinically characterized by two different types of neuro-
logical symptoms [9]. One type, occurring in 90% of
patients, is an acute, transient syndrome characterized
by cramps, paresthesias and dysesthesias that are trig-
gered or enhanced by exposure to cold. The second
type is a chronic [9] and more severe syndrome that is
characterized by the loss of sensory perception and fre-
quently associated with painful sensations that generally
occur after repeated drug administration. The
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induced neurotoxicity remain unclear.
Several studies have examined the neurophysiological,
behavioral and pathological characteristics of oxalipla-
tin-induced peripheral neurotoxicity using rat models
[10] and most of the oxaliplatin-induced pain studies
have been done after a single injection of the drug.
While rats developed significant cold and mechanical
a l l o d y n i af o l l o w i n gas i n g l ed o s eo fo x a l i p l a t i n ,t h e s e
models are not representative of the chronic neurotoxi-
city experienced in clinical practice [11,12]. Cavaletti et
al. [7] demonstrated that chronic oxaliplatin treatment
in rats induced atrophy of dorsal root ganglia (DRG)
neurons and decreased peripheral sensory nerve conduc-
tion velocities (NCV). Moreover, chronic oxaliplatin
treatment induced cold and heat hypersensitivity along
with mechanical allodynia that persisted for 3 weeks
after drug treatment ended [13]. The use of rat models
to study oxaliplatin-induced neurotoxicity has been very
informative. However, since it is difficult to implant
tumors in rats, most studies of the anticancer properties
of oxaliplatin have used mice. Thus, rat models have
limited efficacy for investigations of peripheral neuro-
toxicity in the same experimental paradigms used to
evaluate the anticancer activity of oxaliplatin.
Recently, several mouse models of oxaliplatin-induced
pain have been developed using an acute, single dose
[14,15] or chronic, repeated doses of oxaliplatin [15].
While these studies demonstrated the development of
mechanical and cold allodynia after oxaliplatin treat-
ment [14,15], the characterization of peripheral neuro-
toxicity was limited. To address these limitations we
have performed this study in BALB/c mice treated with
as c h e d u l eo fo x a l i p l a t i na b l et oi n d u c et h eo n s e to fa
painful neuropathy with the aim to achieve a more com-
plete characterization of the peripheral and central ner-
vous system events induced by the chronic treatment.
Results
1. General Appearance and Body Weight Change
To generate the model of oxaliplatin-induced painful
peripheral neuropathy used in this study, the mice were
given tail vein injections of oxaliplatin (3.5 mg/kg) twice
weekly (separated by either 3 or 4 days) for four weeks.
The control group was naïve mice that did not receive
drug or vehicle injections. The duration of this study
was 30 days, during which the mice were continuously
allodynic after receiving oxaliplatin. The oxaliplatin was
generally well-tolerated by the mice. They continued to
groom, make nests, explore their surroundings and
climb on their wire cage tops during the course of drug
treatment, though approximately 20% showed signs of
mild kyphosis and piloerection. The mice were weighed
on drug administration days and, over the course of the
study, the oxaliplatin-treated mice had a significant
decrease in body weight compared to the naïve mice
(Figure 1; day 4, p < 0.05; days 12 and 17, p < 0.01; days
20, 23, 27, p < 0.0001), reaching 15% by the completion
of the study. No mice were euthanized prematurely dur-
ing the course of the study.
2. Nocifensive Response After Oxaliplatin
It is well established that oxaliplatin treatment causes
peripheral neuropathy in humans and neuropathic-like
changes in rats. To determine whether our mouse
model of chronic oxaliplatin treatment-induced neuro-
toxicity also exhibited signs of pain, the mice were
tested for the development of nocifensive responses to
mechanical and thermal stimuli. The mice were ran-
domly assigned to an experimental group and tested for
their baseline nocifensive responses. After the onset of
oxaliplatin treatment, the mice were tested after the sec-
ond dose of drug each week for four weeks.
Mechanical allodynia was defined as a decrease in paw
withdrawal threshold (g) from baseline. The oxaliplatin-
treated mice had a significant decrease in mechanical
threshold after the first week of oxaliplatin treatment
compared to baseline that persisted for at least four
weeks (Figure 2a; Chi Sq. 17.36, df 4, p < 0.001), while
the naïve mice did not (Chi Sq. 0.49, df 4, p > 0.05).
Further, the oxaliplatin-treated mice had a significantly
lower mechanical threshold than the naïve mice after
the first week of oxaliplatin treatment that persisted for
at least four weeks (p < 0.001).
Cold allodynia was defined as an increase in the
threshold temperature (°C) that elicited a jumping
response compared to baseline. The oxaliplatin-treated
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Figure 1 Body weight decreases after oxaliplatin (OHP)
treatment. Mice treated with oxaliplatin3.5 mg/kg/iv twice weekly
(n = 8) lost a significant amount of body weight compared to naïve
mice (n = 8) °p < 0.05, * p < 0.01, ** p < 0.0001 vs. naïve, ANOVA
with repeated measures.
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Page 2 of 13mice had a significant increase in threshold temperature
after the first week of oxaliplatin treatment compared to
baseline that persisted for at least four weeks (Figure 2b;
F = 4.65, df 4, p < 0.01), while the naïve mice did not (F
= 0.25, df 4, p = 0.91). Further, the oxaliplatin-treated
mice had a significantly higher threshold temperature
than the naïve mice after the first week of oxaliplatin
treatment that persisted for at least four weeks (p <
0.05). By contrast, there was no evidence of heat hyper-
algesia (Figure 2c), which was defined as an increase in
the threshold temperature (°C) that elicited a hind paw
licking response. There was no change in heat threshold
from baseline for either the oxaliplatin-treated (F = 0.11,
df 4, p = 0.97) of naïve (F = 0.19, df 4, p = 0.94)
throughout the four weeks. Further, there was no differ-
ence in heat threshold between groups (p > 0.05).
3. NCV, Neuropathological Analysis of DRG and Sciatic
Nerve
The first series of experiments demonstrate that mice
chronically treated with oxaliplatin are not significantly
debilitated by the drug treatment; however, chronic oxa-
liplatin treatment does induce sensitivity to mechanical
and cold stimuli. Thus, this is a valid model to study
chronic oxaliplatin treatment-induced allodynia. Next
we used morphometry and NCV measurements to
determine whether this mouse model of chronic oxali-
platin treatment exhibited neurotoxic changes in the
structure and function of peripheral neurons.
3.1. NCV
After establishing that this mouse model exhibits a pain
phenotype, we next wanted to determine whether altera-
tions in peripheral nerve function could be contributing
to the development of oxaliplatin-induced allodynia. To
assess the functional status of peripheral neurons after
chronic oxaliplatin treatment, the mice were randomly
assigned to experimental groups. NCV and action
potential amplitude were measured in the caudal and
digital nerves 4 days after the final oxaliplatin dose in
week four (Figure 3). Chronic oxaliplatin treatment
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Figure 2 Oxaliplatin (OHP) induces mechanical and cold allodynia but not heat hyperalgesia. (a) Mice treated with oxaliplatin 3.5 mg/kg/
iv twice weekly (n = 8) had a significant decrease in mechanical threshold from baseline and compared to naïve mice (n = 8) that started after
the first week of treatment and persisted for at least four weeks. **p < 0.001 vs. baseline, Friedman Test; #p < 0.001 vs. naïve, Mann Whitney U
Test. (b) Mice treated with oxaliplatin 3.5 mg/kg/iv twice weekly (n = 8) had a significant increase in cold threshold from baseline and compared
to naïve mice (n = 8) that started after the first week of treatment and persisted for at least four weeks. *p < 0.01 vs. baseline, ANOVA with
Repeated Measures; #p < 0.05 vs. naïve, Student’s T Test. (c) Mice treated with oxaliplatin 3.5 mg/kg/iv twice weekly (n = 8) had no change heat
threshold from baseline and were not different from naïve mice throughout the duration of the experiment. P > 0.05 vs. baseline, ANOVA with
Repeated Measures; p > 0.05 vs. naïve, Student’s T Test.
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Figure 3 Oxaliplatin (OHP) decreases NCV in caudal and digital
nerves. (a) Mice treated with oxaliplatin 3.5 mg/kg/iv twice weekly
for four weeks (gray bars; n = 8) had a significant decrease in
caudal NCV compared to naïve mice (black bars; n = 8). (b) The
oxaliplatin-treated mice had a significant decrease in caudal nerve
action potential amplitude compared to naïve mice. (c) The
oxaliplatin-treated mice had a significant decrease in digital NCV
compared to naïve mice. (d) The oxaliplatin-treated mice had no
difference in the amplitude of the digital nerve action potential
compared to naïve mice. **p < 0.0001 vs. naive, #p < 0.001 vs.
naive, Student’s T Test.
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Page 3 of 13induced a significant decrease in the caudal NCV (Fig-
ure 3a; p < 0.0001) with a concomitant significant
decrease in action potential amplitude (Figure 3b; p <
0.01) compared to the naïve group. After oxaliplatin, the
digital NCV also significantly decreased (Figure 3c; p <
0.001), though the action potential amplitude was not
different (Figure 3d), compared to the naïve group.
3.2. Morphological Analysis of DRG and Sciatic Nerve
Next, we wanted to determine whether the altered func-
tion of peripheral neurons after oxaliplatin was accom-
panied by structural changes in the DRG cell bodies and
axons of the sciatic nerve. For this purpose, thin sec-
tions through the L4-L5 DRGs and sciatic nerve from
naïve and oxaliplatin-treated mice were examined at the
light and electron microscope levels two days after the
final dose of drug in week four (Figure 4). Light micro-
scopy revealed that DRG neurons from oxaliplatin-trea-
ted mice had a high incidence of multinucleolated cell
bodies (Figure 4b arrowheads) with eccentric nucleoli
(Figure 4b black arrow) compared to naïve DRG neu-
rons (Figure 4a). In both experimental groups, the cyto-
plasm of neurons and satellite cells appears normal. The
small circular structures with black borders that are evi-
dent between the cell bodies in Figure 4b are radicular
fibers crossing the DRG. These findings were verified by
electron microscopy, which showed nucleolar segrega-
tion in DRG neurons from oxaliplatin-treated (Figure 4d
arrowheads) but not naïve mice (Figure 4c). Examina-
tion of sciatic nerves by light microscope showed that
myelinated fibers in the sciatic nerve of oxaliplatin-trea-
ted mice (Figure 4f, white arrows) had mild changes
indicative of axonopathy, which were not evident in
s c i a t i cn e r v ef r o mn a ï v em i c e( F i g u r e4 e ) .T h e r ew e r e
no changes evident in the unmyelinated fibers from
either group.
Our previous work in rat models demonstrated that
platinum-derived compounds induce DRG neuron cell
body shrinkage [7,16,17]. Since finding that oxaliplatin
induced changes to the nucleoli of DRG neurons in our
mouse model, we performed a morphometric analysis to
examine the cell bodies of DRG neurons from oxalipla-
tin-treated (3.5 mg/kg/iv twice weekly for four weeks)
and naïve control mice for evidence of cell body shrink-
age similar to that seen in rats. The morphometric ana-
lysis revealed that DRG neurons from oxaliplatin-treated
mice (gray bars) had a significant decrease in the area
(mm
2) of their cell bodies (Figure 5a; p < 0.05) and
nucleoli (Figure 5c; p < 0.001), but not nuclei, compared
to DRG neurons from naïve mice (black bars).
4. Electrophysiological Analysis of Wide Dynamic Range
Neurons in the Spinal Dorsal Horn
After determining that chronic oxaliplatin treatment
resulted in altered nocifensive behavior, peripheral nerve
function and structural changes in DRG neuron cell
bodies and sciatic nerve, our next question was to deter-
mine if there was a concomitant change in the activity
of wide dynamic range neurons in the spinal dorsal
horn. Two days after the mice received their final dose
of oxaliplatin (3.5 mg/kg/iv twice weekly) in the fourth
week, the activity of 43 deep dorsal horn neurons (20
neurons from 6 naive and 23 neurons from 6 oxalipla-
tin-treated mice; Table 1) was recorded and analyzed.
Neurons were classified as wide dynamic range based on
their response to innocuous and noxious mechanical sti-
muli applied to the plantar surface of the hind paw ipsi-
lateral to the recording site (Figure 6). During
stimulation, the number of spikes per second (Figure 7;
Table 1) was significantly higher in the oxaliplatin-trea-
ted mice during the innocuous brush (64.93 ± 6.27
spikes/s), moderate pressure (70.59 ± 11.17 spikes/s),
noxious pinch (123.38 ± 14.77 spikes/s) and acetone
(43.09 ± 9.16 spikes/s) stimuli compared to the naive
mice (24.47 ± 4.62, 25.78 ± 5.92, 46.56 ± 9.97, 13.92 ±
3.01 spikes/s respectively; p < 0.001 for brush, press,
pinch; p < 0.01 for acetone).
Discussion
Recent advances in cancer chemotherapy have signifi-
cantly increased the survival rate and time of cancer
patients, although the use of these drugs is also asso-
ciated with an increase in morbidity related to the devel-
opment of painful peripheral neuropathy [18-20].
Oxaliplatin, a third generation platinum derivative, is
one of the most effective chemotherapeutic drugs used
to treat advanced colorectal cancer [21-25]. Unfortu-
nately, oxaliplatin therapy is associated with significant
side effects such as neurotoxicity, which is one of the
most prevalent and dose-limiting effects [26-28], occurs
in greater than 65% of patients and includes mechanical
allodynia and hypersensitivity to cold [29-31]. Oxalipla-
tin-induced peripheral neuropathy (OIPN) occurs in two
forms, acute and chronic. The onset of acute OIPN
occurs either during or within 1-2 days after drug infu-
sion, resolves between cycles and recurs with subse-
quent infusions [25,27]. Chronic OIPN develops as a
cumulative, dose-dependent effect [22,27,32,33] in
patients that receive more than 540 mg/m
2, regardless
of the dosing regimen [23]. The symptoms of chronic
OIPN can be debilitating, persistent and respond poorly
to currently available therapeutics. Thus, it is critical
that we gain a better understanding of the mechanisms
underlying the development and persistence of chronic
OIPN, which could lead to the development of new
treatment modalities to improve symptom management.
The majority of studies examining the neurotoxic
effects of oxaliplatin treatment have been done after
treatment in the rat [7,11,13,34], while the majority of
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Page 4 of 13Figure 4 Oxaliplatin induces nucleolar segregation and axonopathy. (a, b) Light microscopy revealed that DRG neurons from mice treated
with oxaliplatin 3.5 mg/kg/iv twice weekly for four weeks (b; n = 3) had segregated nucleoli (arrow heads) that were eccentric (black arrow)
compared to DRGs from naïve mice (a; n = 3). (c, d) Electron microscopy also showed segregated nucleoli in DRG neurons from oxaliplatin-
treated mice (d; n = 3) but not naïve mice (c; n = 3). Light microscope examination demonstrated that myelinated fibers in the sciatic nerve of
mice treated with oxaliplatin 3.5 mg/kg/iv twice weekly for four weeks (f; n = 3) had evidence of changes indicative of axonopathy (white
arrows) that were not found in sciatic nerve from naïve mice (e; n = 3).
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Page 5 of 13studies examining the antineoplastic efficacy of oxalipla-
tin have been done in mouse. Recently, though, several
studies have been done to examine oxaliplatin-induced
neurotoxicity in the mouse [14,15]. However, the mouse
studies have not closely examined the neurotoxic effects
of chronic oxaliplatin treatment on the status of periph-
eral nerves and spinal dorsal horn neuronal activity. In
this study, we used a mouse model of oxaliplatin-
induced neurotoxicity, based on our preliminary studies
in the rat [7,35], to investigate the effects of chronic
oxaliplatin treatment on nocifensive behavior, peripheral
nerve function and wide dynamic range neuron activity
in the spinal dorsal horn. The dose of oxaliplatin and
the administration schedule were chosen based on pre-
vious work in the rat [7] and preliminary pilot studies in
the mouse. The mice received 3.5 mg/kg/iv twice weekly
for four weeks, which is equivalent to 130 mg/m
2 per
administration and a cumulative dose of 1080 mg/m
2
after 8 cycles. This dose of oxaliplatin and number of
cycles has been found to cause neuropathy symptoms in
patients [23,33,36]. The oxaliplatin treatment did not
affect the general health and functioning of the mice, as
assessed by appearance and activity, though the mice
did lose weight during the course of the study. Although
the weight loss was significant, it was tolerable and con-
sistent with similar rat models [7]. Moreover, the asso-
ciation between the extent of weight loss and peripheral
neuropathy has been ruled out, at least in the rat [37].
However, oxaliplatin treatment did produce significant
mechanical and cold allodynia that persisted for the four
week duration of the study, similar to symptoms
reported by patients [1,9] and to what has been found
in previous studies in the rat [12,13,11,38,39] and mouse
[14,15,40]. Thus, this mouse model of oxaliplatin-
induced neurotoxicity is representative of the human
clinical condition and can be a useful tool to study the
mechanisms that underlie the development and persis-
tence of chronic OIPN.
Oxaliplatin-induced neuropathy has been associated
with damage to the peripheral sensory neurons [7,41],
which leads to alterations in peripheral nerve function
[31,42]. In this study, we found that chronic oxaliplatin
treatment induced a decrease in conduction velocities in
the caudal and digital nerves that was associated with a
concomitant decrease in caudal action potential ampli-
tude. These results are similar to the findings of studies
that were done in the rat [7,43]. Nucleolar morphology
changes were also seen in this study that are similar to
those shown previously [44]. The mechanisms of these
decreases remain unclear and require further study;
however, as suggested by Jamieson and colleagues, one
possibility is that oxaliplatin induces a decrease in phos-
phorylated neurofilaments in DRG neurons with a con-
comitant alterations in sensory axons [45]. Following
the finding that oxaliplatin induced a decrease in NCV
and action potential amplitude; we examined the mor-
phology of DRG neurons and sciatic nerve at the light
and electron microscope levels. Our findings that the
diameter of DRG cell bodies is reduced after chronic
oxaliplatin treatment is also similar to findings in the rat
[7,34,43,45,46], which are suggestive of neuronal atrophy
that could be related to a decrease in phosphorylated
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Figure 5 Oxaliplatin (OHP) treatment causes decreased the area of DRG cell body and nucleolus. Morphometric analysis revealed that
DRG neurons from mice treated with oxaliplatin 3.5 mg/kg/iv twice weekly for four weeks (n = 3) had a significant decrease in the area (mm
2)
of the cell bodies (a) and nucleoli (c) compared to DRG neurons from naïve mice (n = 3). (b) There was no difference in the areas of the nuclei
from oxaliplatin-treated and naïve mice. °p < 0.05 vs naïve, #p < 0.001 vs naïve, Student’s T Test.
Table 1 Oxaliplatin increases activity of wide dynamic range neurons in the spinal dorsal horn.
Treatment Mice Neurons Brush Press Pinch Acetone
Spikes (SEM) Spikes (SEM) Spikes (SEM) Spikes (SEM)
Naive n = 6 n = 20 24.47 (4.62) 25.78 (5.92) 46.56 (9.97) 13.92 (3.01)
Oxaliplatin n = 6 n = 23 64.93 (6.27)** 70.59 (11.17)** 123.38 (14.77)** 43.09 (9.16) #
The peak number of spikes per second were higher in the oxaliplatin-injected mice compared with naïve mice. **p < 0.001 and #p < 0.01 vs. naive, Student’sT
Test.
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Page 6 of 13neurofilament [45]. Finally, our morphological examina-
tion of DRGs and sciatic nerves revealed that many of
the neurons were multinucleolated, that the nucleoli
were eccentric and that rare nerve fibers presented mild
signs of axonopathy. The morphometrical analysis
showed the presence of somatic and nucleolar atrophy
of DRG neurons. Altered DRG neuron morphology and
morphometry have also been found in the rat following
oxaliplatin treatment [44,47]. The underlying mechan-
isms of this phenomenon are unclear; although one
study found that paclitaxel treatment induces nucleolar
e n l a r g e m e n tt h a tc a ni n h i b i tt h en e u r o t o x i ce f f e c t so f
oxaliplatin [47].
Despite these decreases in NCV, the presence of
mechanical and cold allodynia suggests an increase in
peripheral nerve sensitivity [41,48]. The exact mechan-
ism of oxaliplatin-induced hyperexcitability is unclear.
One theory is that a metabolite of oxaliplatin, oxalate,
may alter the functional properties of voltage-gated
sodium channels, which are intrinsic to action potential
generation, resulting in a prolonged open state of the
channels and hyperexcitability of sensory neurons
[49-51]. One possible mechanism underlying the disrup-
tion of voltage-gated sodium channel function is the cal-
cium chelating effect of oxalate, which inhibits
intracellular calcium-dependent mechanisms [13,50]. A
second theory to explain oxaliplatin-induced hyperexcit-
ability, with regard to cold allodynia, is that the sensitiv-
ity and expression levels of transient receptor potential
melastatin 8 (TRPM8) and transient receptor potential
ankyrin 1 (TRPA1) are increased after oxaliplatin treat-
ment [15,52]. TRPM8 is only expressed in the DRG and
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Figure 6 Representative raw data trace of wide dynamic range neurons. Example raw data used to construct a histogram of the stimulus-
response to brush (10 second stimulus), pressure (2 second stimulus) and pinch (2 second stimulus) of an individual wide dynamic range
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Figure 7 Oxaliplatin (OHP) increases activity of wide dynamic
range neurons in the spinal dorsal horn. Two days after the final
injection of oxaliplatin 3.5 mg/kg/iv, the peak number of spikes per
second were higher in the oxaliplatin-injected (gray bars) mice
compared with naïve mice (black bars). **p < 0.001 and #p < 0.01
vs. naive, Student’s T Test.
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Page 7 of 13responds to innocuous cool and noxious cold (<15C°)
temperatures [53-55]. Anand et al. [52] found that oxali-
platin treatment increased the icilin response in cultured
DRG neurons, suggesting that both the TRPM8 and
TRPA1 channels are affected and Gauchan et al. [15]
showed that blocking TRPM8 function by administering
capsazepine inhibited the induction of cold allodynia
after oxaliplatin treatment.
Given that the mice developed mechanical and cold
allodynia after oxaliplatin treatment, our final area of
inquiry was to examine the effects of oxaliplatin on the
activity of wide dynamic range neurons in the spinal
dorsal horn. A variety of neuropathic pain models exhi-
bit increased evoked wide dynamic range (WDR) neuron
activity after nerve injury [56-61]. In this study, mice
that received chronic oxaliplatin treatment had a signifi-
cant increase in wide dynamic range neuron activity
compared to naive mice. Our findings are similar to
those seen in other drug-induced neuropathy models
[56,62] and may reflect physiological changes in the
S D Ha sw e l la si np r i m a r ya f f e r e n t s[ 5 8 , 6 3 ] .T h eo x a l i -
platin-induced increase in WDR neuron activity may be
due to increased neurotransmitter release in the SDH
[64-69], resulting in altered synaptic transmission
[68,70] due to increased neurotransmitter levels.
Increased levels of neurotransmitters, such as brain-
derived neurotrophic factor (BDNF) can activate calcium
permeable 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)
propanoic acid (AMPA) channels, which increase excita-
tory synaptic activity and miniature excitatory post-
synaptic currents (mEPSCs) in the SDH [68,70,71].
Further, increased neurotransmitter levels in the SDH
can lead to a decreased frequency of inhibitory synaptic
events, thus allowing for more excitatory activity [72].
The increase in WDR neuron activity is likely due to
interactions between activated receptors and other sig-
naling molecules [73-76], which results in longer lasting
changes in SDH neurons such as what occurs in central
sensitization [61].
It is well-documented that chemotherapeutic agents
are toxic to the peripheral nervous system, though their
mechanisms of action differ by class. However, many of
the physiological mechanisms that underlie the develop-
ment of chemotherapy-induced neurotoxicity remain
u n c l e a r ,r e g a r d l e s so ft h ec l a s so ft h ed r u g .T h ep l a t i -
num compounds, such as oxaliplatin, target the cell
bodies of the neurons located in the DRG and disrupt
the function of DNA [7,77]. In addition to the mechan-
isms discussed above, oxaliplatin may induce neurotoxi-
city by increasing p53 and p38 activity [78,79]. The
taxanes [80,81], vinca alkaloids [82,83] and epothilones
[84] all seem to exert their neurotoxic effects by inhibit-
ing tubulin function and disrupting axonal transport
and intracellular signaling processes. The symptoms
associated with peripheral neurotoxicity vary by drug
class but all have a significant deleterious effect on the
quality of life of cancer patients that can become dose-
limiting. Thus, it is important that research continues to
increase the understanding of the mechanisms underly-
ing the development of chemotherapy-induced
neurotoxicity.
Conclusions
The findings of this study provide evidence that our
experimental paradigm produced a suitable mouse
model of chronic oxaliplatin-induced neurotoxicity with
mechanical and cold allodynia. Further, this study
demonstrated that chronic oxaliplatin treat induces
hyperexcitability of SDH neurons in addition to the neu-
ropathological changes seen in the DRG and peripheral
nerve. Therefore, this model can be used to further elu-
cidate the mechanisms that underlie the development of
chronic oxaliplatin-induced neuropathy.
Methods
1. Experimental Design
The study was carried out using the same experimental
protocol in 3 separate cohorts of animals (each com-
prised of a naïve group and a drug-treated group) for
the NCV, spinal dorsal horn electrophysiology and beha-
vioral experiments. The neuropathology and morphome-
try experiments were done using the same cohort of
animals that underwent NCV testing. The animals were
randomly divided into experimental groups. In each
experiment, the drug-treated group was administered
oxaliplatin 3.5 mg/Kg twice a week for a 4-week period
with 3 or 4 days-elapsing between the administrations.
The treatment schedule was chosen on the basis of lit-
erature data [40] and of our previous experiments (data
not reported). Since the vehicle used has demonstrated
to be non-toxic (data not reported), naïve control mice
were left untreated.
2. Animals
Young adult female BALB/c mice (~20 g, Harlan, San
Pietro al Natisone, Italy or Harlan Laboratory, Frederick,
M D ,U S A )w e r eu s e df o rt h es t u d y .A l lm i c ew e r e
housed on a 12:12 h light:dark cycle with food and
water available ad libitum in compliance with interna-
tional policies (EEC, 1986; Italian, 1992; U.S. National
Research Council, 1996). The International Association
for the Study of Pain (IASP) guidelines for investigations
of pain in animals was followed [85]. The Institutional
Animal Care and Use Committee of the University of
Maryland School of Medicine and the ad hoc committee
for Animal Studies of the University of Milan-Bicocca
approved these experiments. Throughout the duration
of the study, the mice were visually examined daily for
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Page 8 of 13evidence of debilitation due to drug treatment, which is
indicated by changes in their appearance (disheveled
hair, weight loss and dehydration), behavior (decreased
grooming, eating and drinking) and activity (decreased
exploring and nesting). Any mouse that demonstrated
signs of debilitation would be euthanized; however, no
mice were prematurely euthanized in this study and all
mice were euthanized at the completion of experiments.
3. Drug
Oxaliplatin (gifted by Debiopharm, Lausanne, Switzer-
land) solution was prepared immediately before each
administration. Oxaliplatin was dissolved and diluted in
5% glucose solution. A 10 ml/kg volume, at the concen-
tration of 3.5 mg/kg, was administered intravenously by
tail vein injection. Using Du Bois’s formula to calculate
human body surface area, this dose is equivalent to 130
mg/m
2 per administration and a cumulative dose of
1080 mg/m
2 after 8 cycles. This dose was chosen based
on previous pilot studies (data not reported).
4. Anesthesia
For the NCV measurement and electrophysiological
recording, anesthesia was induced in a chamber with 3%
isoflurane carried in medical air followed by 1-1.5% iso-
flurane delivered by nose cone for maintenance
throughout the procedures, which was adequate to sup-
press the corneal blink response and any withdrawal
response to a noxious stimulus. Additionally, prior to
the laminectomy surgery for the spinal cord electrophy-
siological recordings, mice were given an intraperitoneal
injection of Pentobarbital 40 mg/kg and a local subcuta-
neous injection of marcaine 0.5% (75-100 μl) at the sur-
gical site. Throughout both procedures, the mice
continued to breathe spontaneously at ~2-3 Hz and the
heart rate was maintained at ~9-10 Hz (MouseOx,
S T A R RL i f eS c i e n c e sC o r p . ,O a k m o n t ,P A ) .T h ec o r e
body temperature was continuously monitored and
maintained at ~37°C by a heating pad (Homeothermic
Blanket System, Harvard Apparatus, Holliston, MA) to
avoid isoflurane-induced hypothermia.
5. Tail Vein Injection
The mice were placed in a Broome Style Rodent Restrai-
ner (Plas Labs, Lansing, MI) with the tail extending
from the end. The tail was vasodilated by immersion in
a warm water bath (40-42°C) for 15-30 seconds prior to
injection. A 100 μl Hamilton syringe with a 1/2” 30 g
needle was used for the injection. The lateral tail vein
was located and the tail was firmly immobilized between
the thumb and forefinger. The needle was inserted,
bevel up, at a 10° angle in the rostral direction. The
solution was injected slowly while watching closely for
the vein to blanch, with no detectable swelling of the
tail near the injection site. When the needle was
removed, pressure was applied to the injection site for
15-30 seconds to stop bleeding and minimize hematoma
formation.
6. Assessment of Oxaliplatin-Induced Peripheral
Neurotoxicity
6.1. NCV Measurement
The investigator was blind to the animal conditions for
these experiments. Four days after the last dose of oxali-
platin, caudal and digital NCVs were measured to deter-
mine peripheral sensory/motor nerve functional status.
Using electromyography (Myto2 ABN Neuro, Firenze,
Italy), caudal NCV was determined by placing two prox-
imal recording needle electrodes (one anode and one
cathode) on the tail and two stimulating needle electro-
des 3.5 cm distal to the recording electrodes. Similarly,
the digital NCV was determined in the hind paw by pla-
cing the recording electrodes near the ankle and the sti-
mulating electrodes in the fourth toe near the digital
nerve. The optimal intensity, frequency and duration of
stimulation (10mA, 0.75 sec and 0.04 msec, respectively)
were determined prior to this study to generate high-
quality results. Both the caudal and digital NCVs were
calculated as a ratio (m/sec) of the distance (cm)
between stimulating and recording electrodes and the
time latency (sec.) from the stimulus artifact to the
onset of the elicited action potential. Serial stimulations
with different amplitudes (2-20 mA) were performed to
achieve the maximal action potential feedback. Ten
responses per stimulation amplitude were averaged for
each recording.
6.2. Neuropathological Analysis of DRG and Sciatic Nerve
The investigator was blind to the nerve and DRG condi-
tions for these analyses. Three animals from each group
were sacrificed four days after the last oxaliplatin dose.
The left sciatic nerves and the L4-L5 DRGs were har-
vested and processed following previously reported pro-
t o c o l s ,r e s i ne m b e d d e da n ds e c t i o n e df o rl i g h ta n d
electron microscope analysis [7,16,17,86]. For the light
microscopy analysis, 1 μm semithin sections were
stained with toluidine blue and examined using a Nikon
Eclipse E200 light microscope (Nikon, Firenze, Italy).
For the electron microscopy analysis, ultrathin sections
(80 nm) counterstained with uranyl acetate and lead
citrate, were examined with a Philips CM 10 transmis-
sion electron microscope (Philips, Eindhoven,
Netherlands).
6.3. Morphometric Analysis of DRG Neurons
The investigator was blind to the experimental condi-
tions of the tissue for these experiments. One micron
thick semithin sections stained with toluidine blue were
used for morphometric examination of the DRGs from
control (n = 3) and oxaliplatin-treated mice (n = 3).
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section plane of 50 μm-spaced out sections were consid-
ered to avoid the overlapping of the same cell bodies
and they were analyzed with computer-assisted image
analysis (ImageJ, NIH) to measure the soma, nucleus
and nucleolus size of at least 300 DRG neurons per
mouse following previously reported methods used in
[16].
7. Assessment of Oxaliplatin-Induced neuropathic Pain
7.1. Behavioral Testing - Mechanical Allodynia
The investigator was blind to the animal conditions for
these experiments. The nocifensive behavior of paw
withdrawal from a mechanical stimulus was used to
assess the development of mechanical allodynia. The
mice were placed in individual Plexiglas cubicles on a
wire mesh platform, and allowed to acclimate for
approximately one hour, during which exploratory and
grooming activity ended. A series of von Frey filaments
(Touch Test Sensory Evaluator Kit, myNeurolab.com,
S t .L o u i s ,M O ) ,w i t hb e n d i n gf o r c e st h a tr a n g e df r o m
0.04 g to 1.40 g, was used to deliver the mechanical sti-
muli. Each filament was applied to the hind paw until
the filament just bent and was held in place for 5 sec-
onds or until the mouse withdrew his paw. Each fila-
ment was tested 5 times on each hind paw. A positive
response to the stimulus was defined as a brisk withdra-
wal, with or without shaking or licking, of the hind paw
during or immediately upon removal of the filament
application. The mechanical stimuli were applied to the
plantar surface of each hind paw, starting with the 0.4 g
filament [87]. If the 0.4 g filament elicited 3 positive
responses out of 5 trials, then the mouse was tested
moving downward through the series to the 0.04 g fila-
ment and the number of withdrawals was recorded for
each filament. If the 0.4 g filament did not elicit 3 posi-
tive responses, then the mouse was tested moving
upward through the series to the 1.4 g filament and the
number of withdrawals was recorded for each filament.
Threshold was defined as the filament with the lowest
bending force that elicited at least 3 positive responses
out of 5 trials.
7.2. Behavioral Testing - Heat Hyperalgesia
The investigator was blind to the animal conditions for
these experiments. Using an incremental hot plate
(PE34, IITC Life Sciences; starting temperature 30°C;
ramp set at the maximum rate of 10°C/min), the noci-
fensive behavior of licking the hind paw was used to
identify the threshold for noxious heat. Each mouse was
placed in a Plexiglas cylinder on the metal plate of the
instrument and allowed to acclimate for 30-60 seconds
prior to activating the instrument. The moment the
mouse licked a hind paw, the stimulus was terminated,
the plate temperature immediately returned to 30°C and
the mouse was returned to its home cage. The tempera-
ture of the plate at the time when the licking occurred
was recorded as the outcome measure. This was
repeated after at least 30 minutes elapsing between the
two trials and the mean of the two temperatures was
determined.
7.3. Behavioral Testing - Cold Allodynia
The investigator was blind to the animal conditions for
these experiments. The experimental procedures for the
cold allodynia testing were the same as those used for
the heat hyperalgesia testing. Using an incremental cold
plate (PE34, IITC Life Sciences; starting temperature 30°
C; ramp set at the maximum rate of 10°C/min), the
nocifensive behavior of jumping was used to identify the
threshold for noxious cold. The temperature of the plate
at the time when the mouse jumped was recorded as
the outcome measure. This was repeated after at least
30 minutes elapsing between the two trials and the
mean of the two temperatures was determined.
8. Electrophysiology
The investigator was blind to the animal conditions for
these experiments. Extracellular electrophysiological
recording was done to measure the activity of wide
dynamic range neurons in the spinal dorsal horn. A
laminectomy was performed at the level of the T13-L2
vertebrae to expose the L4-L5 spinal segment 2 days
after the final dose of oxaliplatin. The vertebrae immedi-
ately adjacent to the laminectomy site were clamped
firmly to immobilize the spinal column and minimize
movement of the spinal cord during recording. A pool
around the laminectomy site was formed with 5% agar,
the dura was carefully removed from the cord and the
pool was filled with warm 0.9% saline. Extracellular
potentials were recorded using a fine-tip (<1.0 μm)
tungsten microelectrode (10 MΩ, Frederick Haer Co.,
Brunswick, ME), then amplified and filtered using stan-
dard electrophysiological techniques. Under magnifica-
tion with a surgical dissecting microscope, the electrode
tip was placed on the dorsal surface of the spinal cord
in a vertical position and advanced 400-650 μme l e c t r o -
nically (Model 660 micropositioner, David Kopf Instru-
ments, Tujunga, CA). The Cambridge Electronics
Design (Cambridge, UK) micro 1401 and Spike2 (v6.0)
software were used to acquire and digitize activity. The
search stimulus to identify a unit was continuous strok-
ing with a sable-hair brush on the plantar surface of the
hind paw ipsilateral to electrode placement. To optimize
the amplitude of an identified neuron, the electrode was
moved in the dorsal-ventral plane. When a unit was iso-
lated and its amplitude optimized, the response to
mechanical stimuli was recorded. First, the response to
10-seconds of continuous brushing with the sable-hair
brush was recorded. This was followed by recording the
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wooden probe (10 mm diameter), a 2-second pinch with
blunt forceps and then a drop of acetone applied to the
plantar surface of the hind paw with a 50 μl Hamilton
syringe. At least 30 seconds elapsed between stimulus
applications. Two recordings along the rostral-caudal
axis (moving in the rostral to caudal direction) were
made from most mice. Neuronal activity was discrimi-
nated, sorted and analyzed by principal components
analysis offline using SciWorks (v7.0, Datawave Tech-
nologies, Berthoud, CO) to generate a peristimulus his-
togram with 1-second bins. Stimulus-evoked activity was
quantified by calculating the number of spikes/1-second
bin during the stimulation.
9. Data Analysis
The body weight changes, NCV, morphometric and
electrophysiology data are presented as the mean ± S.E.
M. The body weight changes were analyzed by ANOVA
with repeated measures. The NCV, morphometry and
electrophysiology data were analyzed for significant dif-
ferences between 2 groups by Student’s t-test. The ther-
mal (hot & cold) behavioral data are presented as the
mean ± S.E.M. The data were analyzed for significant
differences between 2 groups by Student’st - t e s ta n d
within groups by ANOVA with repeated measures. The
mechanical behavioral data are presented as ordinal data
and were analyzed using the Mann-Whitney U-test to
identify differences between 2 groups and the Friedman
Test to identify differences with repeated measures
within groups [79]. In all cases, a priori p < 0.05 was
considered significant.
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